Introduction
Diesters of 1,2-benzenedicarboxylic acid (phthalic acid), commonly referred to as phthalates, belong to a group of chemicals with endocrine-disrupting properties, meaning that they can interfere with our normal hormonal balance, potentially resulting in adverse human health effects. A recent state-of-the-science report from the World Health Organization (WHO) provides new evidence for several human health risks from exposure to phthalates and other endocrine disruptors (EDCs) including reproductive health and sexual development (Bergman et al. 2013) .
Phthalates are used as plasticizers in soft polyvinyl chloride (PVC) and found in a large number of commonly used consumer products including food, building materials, plastics, cosmetics, cleaning products, packages, and toys (Bornehag et al. 2005; Dodson et al. 2012; Rudel et al. 2011) . Often, the fraction of phthalates in the plastics is as high as ≥ 30%. Because they are not covalently bound to the product matrix, phthalates can leach into the surrounding environment. As a result they are routinely found in indoor air (Bergh et al. 2011; Rudel and Perovich 2009) and dust (Abb et al. 2009 ; Bornehag et al. 2004 Bornehag et al. , 2005 Langer et al. 2010; Zhang et al. 2013) , and food and water (Shi et al. 2012) .
Phthalates are ubiquitous in the environment, and humans are exposed by multiple routes (oral, dermal, and inhalation), the pathway varying by phthalate. It has recently been shown, for example, that exposure to di(2-ethylhexyl) phthalate (DEHP) is primarily via food and for children also via mouthing of plastics, whereas exposure to diethyl phthalate (DEP) and benzylbutyl phthalate (BBzP) occurs primarily via dermal and inhalation pathways (Carlstedt et al. 2013; Koch et al. 2013; Wittassek et al. 2011) . Robust biomonitoring data show phthalate metabolites in human fluids such as urine, both in children (Langer et al. 2014 ) and adults (Wittassek et al. 2011 ), blood (Frederiksen et al. 2010; Wan et al. 2013) , and breast milk (Fromme et al. 2011) . These compounds have also been found in amniotic fluid, suggesting that they cross the placental barrier and expose the fetus .
One complication in studying phthalate exposure is that replacement of phthalates is continuously ongoing as risks are reported for older formulations. One example of this is the introduction of diisononyl phthalate (DiNP) and more recently diisononyl cyclohexane-1,2-dicarboxylate (DINCH) to replace DEHP in soft PVC [European Chemicals Agency (ECHA) 2013] . Recent biomonitoring data show that urinary levels of DEHP metabolites are decreasing while DiNP metabolites are increasing in European (Göen et al. 2011) and American populations (Silva et al. 2013) .
Phthalates and reproductive health. The impact of endocrine-disrupting chemicals on male reproductive health has been a research focus for almost 20 years. During that time, multiple studies in laboratory animals (since 1995) (Sharpe et al. 1995) and in humans (since 2005) (Swan et al. 2005 ) have demonstrated the sensitivity of the developing male reproductive system to several phthalates. Phthalates may reduce the production of androgens by the testis and rodent studies have demonstrated that DEHP and dibutyl phthalate (DBP) disrupt androgen signaling when administered in the critical window for the development of the reproductive tract (MacLeod et al. 2010; van den Driesche et al. 2011) . In humans, similar findings suggest that phthalates (e.g., DEHP and DBP) may be related to male reproductive and developmental abnormalities (ECHA 2013) .
Anogenital distance and phthalate exposure. Anogenital distance (AGD)-the distance from the anus to the genitals-is a marker that has been used in animal studies to assess reproductive toxicity (U.S. Environmental Protection Agency 1996). AGD is a sexually dimorphic trait that develops in utero under androgen control and is 50-100% longer in males than females.
Numerous studies have shown that prenatal phthalate exposure (notably DEHP, DBP, BBzP) shortens male AGD in rodents (Foster 2005; van den Driesche et al. 2011) . Only a few human studies have examined prenatal phthalate exposure and AGD. The first to examine this association in humans reported significant inverse relationships Background: Phthalates are used as plasticizers in soft polyvinyl chloride (PVC) and in a large number of consumer products. Because of reported health risks, diisononyl phthalate (DiNP) has been introduced as a replacement for di(2-ethylhexyl) phthalate (DEHP) in soft PVC. This raises concerns because animal data suggest that DiNP may have antiandrogenic properties similar to those of DEHP. The anogenital distance (AGD)-the distance from the anus to the genitals-has been used to assess reproductive toxicity. oBjective: The objective of this study was to examine the associations between prenatal phthalate exposure and AGD in Swedish infants. (Swan et al. 2005) ; and a later publication with a larger sample size and more powerful statistical methods found associations between male end points and metabolites of DEHP (Swan 2008) . Recently a relationship between prenatal DEHP exposure and shorter AGD in male newborns was reported from Japan (Suzuki et al. 2012) and from Mexico (Bustamante-Montes et al. 2013 ). However, a study from Taiwan found a negative association between prenatal monobutyl phthalate (MBP) exposure and AGD in newborn girls but not in boys (Huang et al. 2009 ). To date no studies in humans have included metabolites of DiNP.
Aim of the study. Animal data suggest that DiNP may have antiandrogenic properties similar to those of DEHP (Boberg et al. 2011) . This raises concerns because DiNP has been introduced to replace DEHP, and consequently DiNP exposure is rapidly increasing in populations globally. Although several studies have examined phthalates and AGD in humans, none has included DiNP. Therefore, in the present study we examined the relationship between first-trimester urinary metabolite concentrations of DEP, DBP, DEHP, and BBzP as well as DiNP in relation to anogenital distance in boys at 21 months of age.
Methods
Description of the SELMA study. The Swedish Environmental Longitudinal, Mother and child, Asthma and allergy (SELMA) study is a prospective birth cohort study in Sweden that includes > 2,000 mother-child pairs followed from early pregnancy (Bornehag et al. 2012) . The study aim was to investigate the impacts of early-life exposure to endocrine-disrupting chemicals and other exposures, for multiple outcomes of growth, development, and chronic diseases.
The SELMA cohort was established by recruiting women in the 10th week of pregnancy in the county of Värmland, Sweden, between September 2007 and March 2010. Of 8,394 reported pregnant women, 6,658 were invited to participate in the study. Among the invited women, 2,582 agreed to participate, corresponding to a participating rate of 39%. Of the 4,076 nonparticipants, 2,091 women were invited to complete a nonrespondent questionnaire for us to examine possible selection bias. We found a self-selection bias in the established cohort when compared with the nonparticipant group-participating families smoked less (14% vs. 19%), had more frequent asthma and allergy symptoms in the family (58% vs. 38%), had higher education (university level) among the mothers (51% vs. 36%), and more often lived in single-family houses (67% vs. 60%). However, there was no obvious reason that this selection bias would have an impact on identification of environmental risk factors for health effects. Detailed recruitment procedures, selection criteria, and data relating to selection bias have been reported and discussed elsewhere (Bornehag et al. 2012) . Biological samples (blood and urine) have been collected from the 2,582 pregnant women and their children. Information related to lifestyles, socioeconomic status, living conditions, diet, and medical history has been collected using annual questionnaires (Bornehag et al. 2012) .
Measurements of AGD in baby boys. Boys born between 1 September 2009 and 20 November 2010 (i.e., those who were < 18 months of age in the SELMA study) (n = 325) and their parents were invited to participate in the study; of these, 228 participated (70%). Of these we were able to measure AGD in 225 boys, and of these, 196 children are included in the present analyses. Mean age of the 196 boys was 20.8 months. AGD was measured by two nurses (one pediatric staff nurse and one midwife) from the County Council of Värmland who were trained by research staff from The Infant Development and the Environment Study (TIDES) (Barret et al. 2014) . The nurses had no knowledge of the mother's phthalate concentrations. All AGD measurements were made in the baby's home or at a pediatric clinic.
We obtained two measurements of AGD using measurement methods that have been described elsewhere (Sathyanarayana et al. 2010) . Briefly, the longer AGD measurement (AGDap) was measured from the center of the anus to the anterior base of the penis, and the shorter (AGDas) from the center of the anus to the posterior base of the scrotum. The infant was placed on his back on a flat surface with his hips relaxed outward and pulled back towards his shoulders by his mother or an assistant. The examiner stood in front of the infant and made three measurements of both long and short AGD with a dial caliper; the coefficient of variation (CV) was calculated for each AGD measure. Only one measurement was made for 12 boys regarding AGDas and for 24 boys regarding AGDap.
Phthalate metabolites in first-trimester urine. Of the 2,582 pregnant women participating in the SELMA study, a first morning urine sample was obtained from 2,356 women (91%) during weeks 9-11 of the pregnancy. The urine samples were stored frozen at -20°C. These samples were analyzed for the 10 phthalate metabolites listed in Table 1 . Briefly, 0.2 mL of urine were added with 0.1 mL of ammonium acetate (pH 6.5) and 0.01 mL glucoronidase (Escherichia coli) and thereafter incubated at 37°C for 30 min. Then we added 0.05 mL of a 50:50 (vol:vol) water and acetonitrile solution of labeled ( 3 H or 13 C) internal standards of all analyzed compounds. A C18 column (2.1 mm i.d. × 50 mm; Genesis Lightn; Grace, Deerfield, IL, USA) was used before the injector to reduce the interference of contaminants during the mobile phase. The phthalate metabolites in the samples were separated on a C18 column (1.5 μm, 2.0 mm i.d. × 30 mm VisionHT; Grace). The mobile phases were water and acetonitrile with 0.08% formic acid. The samples were analyzed on a Shimadzu UFLC system (Shimadzu Corporation, Kyoto, Japan) coupled to a QTRAP5500 triple quadrupole linear ion trap mass spectrometer equipped with a TurboIon Spray source (AB Sciex, Foster City, CA, USA). The samples were analyzed in triplicate, and the Mazzachi et al. (2000) . We calculated the sum of DEHP and DiNP metabolites by summing the metabolite concentrations on a molar basis. Statistical analyses. Urinary levels of phthalate metabolites were log-transformed to normalize distributions and geometric means (GMs) with 95% confidence interval (CIs). Associations between log-transformed phthalate metabolite concentrations and AGD were estimated using a general linear model, and we present the beta coefficients with 95% CI. We also categorized covariateadjusted AGD (AGDas and AGDap) into "short" (< 25th percentile), "medium" (25th-75th percentile), and "long" (≥ 75th percentile) as a reference. We then used logistic regression models to estimate the odds ratio (OR) of having a boy with a short (adjusted) AGD compared with a long AGD as a function of log-transformed concentrations of phthalate metabolites in prenatal urine. Finally we examined the ORs for having a short AGD compared with a long AGD as a function of quartiles of phthalate metabolite concentration in the pregnant women's urine, with the lowest quartile as a reference. Therefore, using these models we examined the relation between prenatal phthalate exposure and AGD in three ways: a) both AGD and phthalate metabolite concentrations modeled as continuous variables; b) categorical AGDs vs. continuous phthalate metabolite concentrations; and c) both AGD and phthalate metabolite concentrations modeled as categorical variables (Figure 1) .
The literature indicates that both age and body size can influence measures of AGD. Thus, we controlled for body size by using weight-for-age percentiles by the use of WHO standards (WHO 2009). Weightfor-age percentiles are correlated with age, but much less correlated than weight and age (Swan 2008) . Finally, in addition to weight-for-age, all models were adjusted for the boy's age at examination (months), gestational week of urine sampling, and urinary creatinine concentration. A p-value < 0.05 was considered statistically significant.
Ethical approval. The research ethics committee at Uppsala University, Sweden, approved the study, and informed consent was obtained from all participating adults.
Results
Study population. The study population for this analysis was quite similar to the entire SELMA study population. The 196 families included in the final analysis were somewhat better educated, smoked less, and were more likely to live in a single-family house and in a rural setting (Table 2) .
AGD. AGD was measured on 225 boys (19-21 months of age) between June 2011 and August 2012, and prenatal phthalates metabolites were available for 199 of them. Of these, one child was excluded due to an error in weight measurements and two children were excluded due to a CV for the AGD measurements > 10%, resulting in a study population of 196 children. These 196 boys had a mean age of 20.8 months and a mean weight of 12.6 kg. In addition, AGDap was not measured on four of these boys, so for those analyses n = 192 (Table 3) . The median AGDas was 40.7 mm [interquartile range (IQR) = 37.8-45.0 mm] while the median AGDap was 82.6 mm (IQR = 78.0-87.4 mm). The mean CV was 2.3% for AGDas and 1.6% for AGDap (Table 3) .
Phthalate metabolites. Ten phthalate metabolites and creatinine were measured in urine collected during weeks 9-11. The GM and 95% CI for the concentration of the 10 metabolites as well as the sum of DEHP and DiNP metabolites are presented in Table 4 . All phthalate metabolites were identified above LOD in all urine samples ( Table 1 ). The distribution of the metabolite concentrations in the AGD study population was comparable with the distribution in the entire SELMA cohort (n = 2,356) (data not shown). Table 4 also provides unpublished data reflecting urinary levels of phthalate metabolites in pregnant women of boys and girls from the Study for Future Families (SFF), whereas published data reflect boys only (Swan 2008 ; (Table 5) .
These associations were also seen when AGD was stratified and phthalate concentrations were compared by adjusted AGD quartile (Table 6 ). The ORs for having an AGDas in the 2nd-3rd quartile when compared with the 4th quartile as a function of (log-transformed) DiNP metabolite concentrations were in the range of 1.1-1.2 but nonsignificant, whereas the ORs for having an AGDas in the 1st quartile when compared with the 4th quartile was in the range of 2.6-3.1 and significant. We also saw weaker inverse associations between AGDap and DINP metabolites, which did not reach statistical significance. Associations between prenatal DEHP metabolite exposure and shorter AGDas were also seen, though these associations did not reach statistical significance.
Finally, the odds of having a short AGDas (in the 1st quartile) when compared with a long AGDas (4th quartile) as a function of quartile of phthalate metabolite concentration showed a linear dose-response relationship for prenatal DiNP metabolite exposure ( Figure 1A ). Similar but somewhat weaker associations were seen between AGDas and DEHP metabolites, as well as well as MBzP metabolites, whereas no associations were seen with MEP and MBP metabolites. No consistent patterns were seen between AGDap and any of the phthalate metabolites ( Figure 1B ).
Discussion
Our finding that prenatal phthalate exposure is associated with shorter male AGD is consistent with several earlier studies. However, Swan (2008) found associations between a shorter male AGD and prenatal exposure, particularly for DEHP metabolites, in mothers recruited in 2000-2003, whereas we saw a stronger association with DiNP metabolites. Mothers of the 196 boys included in the current analysis were pregnant in 2009-2010. Phthalates in commerce changed a Data from a questionnaire at week 10 of pregnancy when urine samples were collected from the pregnant women (n = 1,974).
considerably between 2000 and 2010. Since then, DiNP has largely replaced DEHP in soft PVC applications such as flooring materials, and was measureable in 100% of the current mothers. Additionally, in the present study we observed associations primarily with the shorter AGD measure (AGDas) whereas in the SFF study associations were stronger for AGDap (Swan 2008 )-a difference that may be attributable partly to subtle differences in measurement methods between the two studies, but is largely unexplained. The inverse association between prenatal DiNP exposure and AGDas was significant, as expressed in Table 5 , but the AGDas reduction was small in relation to the quite large increase in exposure. For example, more than an IQR increase in DiNP exposure (Table 4) was related to a 4% (1.69 mm) reduction in AGDas in the model (Table 5) . About the same effect size has been found for DEHP exposure and AGD reduction in the SFF study (Swan 2008) . However, such small relative differences have been associated with male genital birth defects and impaired reproductive function in adult males, as described below.
Our finding of an association between AGD and prenatal exposure to DiNP, and to a lesser extent to DEHP (nonsignificant), is not unexpected. DEHP is a known antiandrogen (Foster 2005; Gray et al. 2000) , and DiNP may be as well. Prenatal DiNP reduces testosterone production in Harlan rat pups (Hannas et al. 2011) , although it is reported to be a less potent antiandrogen than DEHP. Furthermore, DiNP exposure in rats during gestation and perinatally increased the incidence of reproductive malformations in male offspring and caused alterations in fetal testicular testosterone production (Borch et al. 2004; Gray et al. 2000) . In addition, DiNP is an analog of DEHP-the reason for replacing DEHP with DiNP in soft PVC is that the two molecules have common chemical properties, which may also include antiandrogenic action. Our finding is also in line with some animal data. Prenatal exposure to DiNP has been found to reduce anogenital distance in male offspring rats in three studies; in Wistar rats (Boberg et al. 2011) , in Wistar Imamichi rats (Lee et al. 2006) , and in Sprague-Dawley rats (Ostby et al. 2001) . In another study by Clewell et al. (2013b) , AGD was reported to be reduced, but only on postnatal day 14 and at the highest exposure level. Boberg et al. (2011) found similar dose-related effects of DiNP as those previously shown for DEHP and DBP. They stated that their finding supports the conclusion that DiNP has antiandrogenic properties and is therefore a reproductive toxicant. However, they also stated that DiNP appears to be less potent than DEHP and DBP. On the other hand, in three other studies no association was found between prenatal DiNP exposure and AGD in offspring rats (Clewell et al. 2013a; Gray et al. 2000; Masutomi et al. 2004) .
AGD measurements in SELMA boys were longer than those in SFF (Swan 2008; Swan et al. 2005) . Median AGDap was 82.6 mm in SELMA and 70.2 mm in SFF; median AGDas was 40.7 mm in SELMA and 36.8 mm in SFF. These differences are at least partly attributable to difference in age at examination; boys in SELMA averaged 20.8 months of age compared with 12.8 months in SFF. The other three studies reporting associations between prenatal phthalate exposure and AGD in offspring children are not comparable with ours because AGD in those studies was measured at birth (Bustamante-Montes et al. 2013; Sathyanarayana et al. 2010; Suzuki et al. 2012) .
Prenatal urinary levels of phthalate metabolites in the 196 mothers were comparable with those in the entire SELMA cohort, suggesting that there was no substantial selection bias (data not shown). The urinary levels of most phthalate metabolites are comparable with those in SFF and NHANES, but there are differences. MBP metabolite levels are higher in Swedish pregnant women (SELMA), whereas MEP is higher in pregnant women in the United States (SFF, NHANES). MBzP (monobenzyl phthalate) metabolites levels are slightly higher in Sweden whereas the picture for DEHP metabolites is less clear, with both higher and lower levels in Swedish data (Table 4) . There are no data for DiNP metabolites in SFF. However, based on more recent data for the DiNP metabolite cx-MMeHP 
